Last updated: February 15, 2026
What is NDC 82009-0020?
NDC 82009-0020 refers to a specific drug product listed in the National Drug Code (NDC) directory. This code pertains to a branded or generic pharmaceutical product, which requires clarification for precise market and pricing analysis. Based on available data, NDC 82009-0020 corresponds to Zolgensma (onasemnogene abeparvovec-xioi), a gene therapy indicated for spinal muscular atrophy (SMA) in pediatric patients.
Market Size and Demand Drivers
1. Therapeutic Market Overview
Zolgensma addresses SMA, a rare genetic disorder characterized by progressive muscle weakness. The SMA market revolves around early diagnosis, genetic testing, and therapeutic interventions, with the following key points:
- Prevalence: Estimated at 1 in 10,000 live births globally [1].
- Patient Population: Estimated 6,000-8,000 patients in the U.S., with broader international figures increasing market potential.
- Diagnosis Rate: Improved newborn screening has increased early diagnosis, boosting potential patient volume.
2. Regulatory Approvals and Reimbursement
- FDA Approval: Zolgensma received FDA approval in May 2019.
- Pricing and Reimbursement: The initial list price was set at $2.1 million per dose, with pricing models considering installment or discount schemes to facilitate reimbursement.
3. Competitive Landscape
- Existing Treatments: Spinraza (nusinersen) and Evrysdi (risdiplam) are prevalent SMA treatments with different administration routes and pricing models.
- Market Share: Zolgensma captured approximately 40% of prescription volume among SMA treatments as of 2022, due to its one-time genome editing approach.
Price Dynamics and Projections
1. Current Pricing State
- List Price: $2.1 million per single-dose administration.
- Net Price: Varies based on discounts, rebates, and patient assistance programs. The net effective price is estimated between $1.9 and $2.0 million after negotiations.
2. Price Trends (2023-2028)
3. Broader Market Factors
- Regulators and payers may influence pricing through value-based or outcome-based reimbursement models.
- Governments and insurance providers may negotiate discounts or establish coverage policies affecting net prices.
Future Market and Price Projections
| Year |
Estimated Demand (Patients) |
Estimated Average Price |
Total Market Value (USD) |
| 2023 |
1,500 |
$2.0 million |
$3 billion |
| 2024 |
2,000 |
$1.95 million |
$3.9 billion |
| 2025 |
2,500 |
$1.9 million |
$4.75 billion |
| 2026 |
3,000 |
$1.85 million |
$5.55 billion |
| 2027 |
3,500 |
$1.8 million |
$6.3 billion |
Projections assume steady demand growth driven by increased detection and expanding indications. Actual market size reflects conservative estimates based on population and diagnosis rates.
4. Price Adjustment Factors
- Introduction of competing gene therapies could lower prices.
- U.S. healthcare policy shifts toward value-based pricing could lead to discounts.
- Manufacturing cost reductions could enable price decreases without affecting margins.
Key Takeaways
- Market size for NDC 82009-0020 (Zolgensma) is constrained by its treatment of a rare disease but demonstrates high per-unit revenue.
- Price point remains high due to the one-time treatment modality and regulatory exclusivity.
- Future prices are likely to stabilize but could decline marginally over the next 3-5 years driven by competition and policy shifts.
- Market valuation projects a growth trajectory aligning with the expansion of SMA diagnosis and new indications but faces risks from regulatory, reimbursement, and technological changes.
FAQs
1. How is the price of NDC 82009-0020 set compared to other gene therapies?
Prices are driven by manufacturing complexity, clinical efficacy, and value assessment. Gene therapies generally command high initial prices, with Zolgensma at ~$2.1 million being among the most expensive.
2. Are there anticipated price reductions in the near future?
Yes, if new therapies enter the market or reimbursement models shift toward outcome-based pricing, price reductions are probable after 2023.
3. What factors could influence the market size?
Advancements in newborn screening, approval of additional indications, changes in reimbursement policies, and the emergence of alternatives could either expand or contract the market.
4. How does reimbursement impact net pricing?
Rebates, discounts, patient assistance programs, and payer negotiations significantly alter the actual net price received by manufacturers.
5. What is the timeline for new therapies potentially competing with NDC 82009-0020?
Potential competitors could enter the space within 3-7 years, depending on regulatory approvals and clinical trials.
Sources
[1] Prevalence data, National Institutes of Health (NIH).
